RxDoctor Payments Data

Michael Mawby, MD

Rheumatology · Traverse City, MINPI 1720084114

Payments from drug & device makers

$6,791in general payments, 2019–2025

Across 158 payments — averaging $42.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$3K
  • Johnson & Johnson$741
  • AbbVie$646
  • Novartis$628
  • Amgen$542
  • Pfizer$215
  • plus $637 from 12 others

What the payments were for

  • Food & beverage$2,99788%
  • Education$41212%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,791 in reported general payments places this provider in the 60th percentile of 195 rheumatology providers in Michigan.

See all rheumatology providers in Michigan

Medicare billing

Part B allowed, 2024
$1,360,628
Medicare patients
276
Services billed
73,181

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept78$588,076
Humira(Cf) PenAdalimumab46$340,649
Humira PenAdalimumab26$263,966
EnbrelEtanercept29$213,085
Cosentyx Sensoready (2 Pens)Secukinumab14$105,105
Enbrel MiniEtanercept14$93,634
RinvoqUpadacitinib14$88,423
Orencia ClickjectAbatacept11$68,186
Cimzia (2 Pack)Certolizumab Pegol12$65,898
Xeljanz XrTofacitinib Citrate11$60,735
Actemra ActpenTocilizumab13$58,616
Hydroxychloroquine Sulfate470$32,400
MethotrexateMethotrexate Sodium264$15,374
Leflunomide26$3,106
Sulfasalazine DrSulfasalazine26$3,015

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenEnbrel$542$213,08529 claims
AbbVieRinvoq$646$88,42314 claims
UCB, Inc.Cimzia (2 Pack)$12$65,89812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 195 rheumatology providers in Michigan.

Other rheumatology in Traverse City

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →